Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593976 | 0.85 | PKM (0.35) | PKMNPSR1LMNATSHRHSD17B10 | |
| SCHEMBL18202952 | 0.83 | CYP4F2 (0.33) | NPSR1LMNATSHRHSD17B10MEN1 | |
| SCHEMBL17221436 | 0.82 | CYP4F2 (0.35) | NPSR1LMNATSHRHSD17B10MEN1 | |
| SCHEMBL24940535 | 0.80 | LMNA (0.32) | PKMNPSR1LMNATSHRHSD17B10 | |
| SCHEMBL20456312 | 0.80 | CYP4F2 (0.34) | NPSR1LMNATSHRHSD17B10MEN1 | |
| SCHEMBL23146582 | 0.80 | LMNA (0.32) | NPSR1LMNATSHRHSD17B10MEN1 | |
| SCHEMBL14087273 | 0.80 | CHRM1 (0.39) | PKMNPSR1LMNACYP4F2CYP4A11 | |
| SCHEMBL9154034 | 0.80 | NPSR1 (0.41) | NPSR1LMNATSHRHSD17B10MEN1 | |
| SCHEMBL5084605 | 0.80 | NPSR1 (0.41) | NPSR1LMNATSHRHSD17B10MEN1 | |
| SCHEMBL23539828 | 0.78 | CYP4F2 (0.41) | NPSR1LMNATSHRHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | PKM 3072/4885NPSR1 4198/4885LMNA 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.